Legato Capital Management LLC Purchases 1,496 Shares of Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS)

Legato Capital Management LLC boosted its holdings in shares of Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) by 3.4% during the 4th quarter, HoldingsChannel.com reports. The fund owned 45,656 shares of the company’s stock after purchasing an additional 1,496 shares during the period. Legato Capital Management LLC’s holdings in Tarsus Pharmaceuticals were worth $2,528,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. SG Americas Securities LLC lifted its holdings in shares of Tarsus Pharmaceuticals by 87.5% during the 3rd quarter. SG Americas Securities LLC now owns 7,242 shares of the company’s stock valued at $238,000 after purchasing an additional 3,379 shares in the last quarter. Creative Planning acquired a new stake in Tarsus Pharmaceuticals during the 3rd quarter worth approximately $362,000. Allspring Global Investments Holdings LLC lifted its stake in Tarsus Pharmaceuticals by 16.3% in the third quarter. Allspring Global Investments Holdings LLC now owns 210,531 shares of the company’s stock valued at $6,924,000 after buying an additional 29,465 shares in the last quarter. Assenagon Asset Management S.A. boosted its holdings in shares of Tarsus Pharmaceuticals by 7.3% in the third quarter. Assenagon Asset Management S.A. now owns 1,141,247 shares of the company’s stock valued at $37,536,000 after buying an additional 77,825 shares during the period. Finally, E. Ohman J or Asset Management AB boosted its holdings in shares of Tarsus Pharmaceuticals by 20.5% in the third quarter. E. Ohman J or Asset Management AB now owns 46,981 shares of the company’s stock valued at $1,545,000 after buying an additional 8,000 shares during the period. 90.01% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several equities research analysts recently commented on TARS shares. Guggenheim reaffirmed a “buy” rating on shares of Tarsus Pharmaceuticals in a research report on Monday. The Goldman Sachs Group boosted their price target on Tarsus Pharmaceuticals from $36.00 to $41.00 and gave the company a “neutral” rating in a report on Friday, November 15th. Oppenheimer upped their price objective on Tarsus Pharmaceuticals from $65.00 to $72.00 and gave the stock an “outperform” rating in a research report on Wednesday, January 22nd. Finally, Barclays lifted their target price on Tarsus Pharmaceuticals from $60.00 to $62.00 and gave the company an “overweight” rating in a research report on Monday, January 27th. One research analyst has rated the stock with a hold rating, five have issued a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, the company has a consensus rating of “Buy” and a consensus price target of $56.00.

Tarsus Pharmaceuticals Trading Down 1.0 %

Shares of NASDAQ TARS opened at $51.22 on Wednesday. Tarsus Pharmaceuticals, Inc. has a fifty-two week low of $20.08 and a fifty-two week high of $57.28. The company has a debt-to-equity ratio of 0.30, a quick ratio of 5.38 and a current ratio of 5.42. The business has a 50-day moving average of $52.05 and a 200-day moving average of $41.22.

Tarsus Pharmaceuticals Profile

Tarsus Pharmaceuticals, Inc, a commercial stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for eye care in the United States. The company's lead product candidate is XDEMVY, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease.